HDAC inhibitor chidamide synergizes with venetoclax to inhibit the growth of diffuse large B-cell lymphoma via down-regulation of MYC, BCL2, and TP53 expression

In this study the synergistic mechanism of chidamide and venetoclax in DLBCL was determined through in vitro and in vivo models. We found that combination therapy significantly reduced the protein levels of MYC TP53 and BCL2 in activated apoptotic-related pathways in DLBCL cells by increasing BIM levels and inducing cell apoptosis. Moreover combination therapy regulated expression of multiple transcriptomes in DLBCL cells involving apoptosis cell cycle phosphorylation and other biological processes and significantly inhibited tumor growth in DLBCL-bearing xenograft mice. Taken together these findings verify the in vivo therapeutic potential of chidamide and venetoclax combination therapy in DLBCL warranting pre-clinical trials for patients with DLBCL.
Source: Journal of Zhejiang University. Science. B. - Category: Universities & Medical Training Source Type: research